Affinage

RBMS1

RNA-binding motif, single-stranded-interacting protein 1 · UniProt P29558

Length
406 aa
Mass
44.5 kDa
Annotated
2026-04-28
100 papers in source corpus 11 papers cited in narrative 11 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RBMS1 is an RNA-binding protein that functions as a multifaceted post-transcriptional regulator of mRNA stability and translation, with additional roles in single-stranded DNA binding at gene regulatory elements. RBMS1 directly binds target mRNAs to control their stability—stabilizing transcripts such as B4GALT1 to maintain PD-L1 glycosylation and immune evasion, and suppressing metastasis-promoting programs in colon cancer (PMID:32513775, PMID:35538152). RBMS1 also promotes translation of specific mRNAs by bridging 3′- and 5′-UTRs via interaction with eIF3d (as shown for SLC7A11 mRNA, linking RBMS1 to ferroptosis regulation through cystine uptake) and by cooperating with the m6A reader YTHDF1 to enhance S100P translation and metastasis in NSCLC (PMID:34609966, PMID:38342601). Through its RRM domains, RBMS1 also binds single-stranded DNA at the c-myc replication origin to stimulate DNA replication and binds a negative cis-element in the α-smooth muscle actin promoter to suppress transcription (PMID:7838710, PMID:9580695).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 1994 Medium

    The foundational question of what RBMS1 (MSSP-2) binds and whether it has a direct biochemical activity was answered: RBMS1 binds single- and double-stranded DNA at the c-myc replication origin via its RRM domains and stimulates DNA replication in vitro, establishing it as an RRM-containing nucleic acid-binding protein with replication-stimulatory activity.

    Evidence cDNA cloning, bacterially expressed deletion mutants, DNA binding assays, and SV40 plasmid replication assay

    PMID:7838710

    Open questions at the time
    • In vitro replication assay only; physiological relevance of replication stimulation unconfirmed
    • No RNA-binding function yet explored
    • Single lab foundational study
  2. 1998 Medium

    Whether RBMS1 could function as a transcriptional regulator was addressed: the chicken ortholog (MSSP-1) binds a single-stranded negative cis-element in the α-smooth muscle actin promoter and suppresses its transcriptional activity, extending RBMS1 function beyond replication to transcriptional repression.

    Evidence Gel shift assay, Southwestern blotting, promoter-reporter overexpression in cultured smooth muscle cells

    PMID:9580695

    Open questions at the time
    • Ortholog study; human RBMS1 function at this promoter not tested
    • Mechanism of transcriptional suppression (e.g., competition with activators) not defined
    • No in vivo validation
  3. 2012 Medium

    Whether RBMS1 operates in a regulatory network controlling specific physiological outputs was clarified: miR-383 targets RBMS1 to reduce c-Myc levels and modulate steroidogenesis in ovarian granulosa cells, establishing RBMS1 as a node in post-transcriptional gene regulation with endocrine consequences.

    Evidence miRNA overexpression, luciferase reporter assay, mRNA stability assay, steroidogenesis assay in mouse granulosa cells

    PMID:22593182

    Open questions at the time
    • RBMS1-to-c-Myc mechanism (direct mRNA binding vs. indirect) not fully resolved
    • Mouse model only
    • Upstream miR-383 regulation context-dependent
  4. 2020 High

    A key question—whether RBMS1 directly controls mRNA stability with disease-relevant phenotypic consequences—was definitively answered: RBMS1 directly binds target mRNAs to regulate their stability, and its loss increases metastatic capacity in colon cancer xenograft models, establishing RBMS1 as a metastasis suppressor acting through post-transcriptional mRNA stabilization.

    Evidence PRADA transcriptomic framework, RBMS1 knockdown/overexpression in xenograft mouse models, direct mRNA binding assays

    PMID:32513775

    Open questions at the time
    • Specific mRNA targets and binding motifs not comprehensively catalogued
    • Mechanism of stability regulation (decay pathway involvement) not defined
  5. 2021 High

    How RBMS1 promotes translation of specific mRNAs was mechanistically resolved: RBMS1 bridges the 3′- and 5′-UTR of SLC7A11 mRNA via direct interaction with translation initiation factor eIF3d, promoting cap-independent-like translation; RBMS1 ablation inhibits SLC7A11 translation, reduces cystine uptake, and triggers ferroptosis in lung cancer cells.

    Evidence Co-immunoprecipitation, shRNA knockdown, in vitro translation assays, xenograft mouse models

    PMID:34609966

    Open questions at the time
    • Whether eIF3d bridging is a general mechanism for other RBMS1 mRNA targets is unknown
    • Structural basis of RBMS1-eIF3d interaction not resolved
  6. 2022 High

    Multiple studies in 2022 expanded RBMS1's functional repertoire: (1) RBMS1 stabilizes B4GALT1 mRNA to maintain PD-L1 glycosylation, and its loss promotes PD-L1 degradation and anti-tumor immunity in TNBC; (2) RBMS1 interacts with MYC at the IL-6 promoter to transactivate IL-6/JAK2/STAT3 signaling in gastric cancer; (3) circEXOC6B scaffolds RBMS1 and HuR to increase AKAP12 expression and suppress prostate cancer metastasis.

    Evidence shRNA screens, mRNA stability assays, ubiquitination assays, syngeneic mouse models (PMID:35538152); ChIP, Co-IP, xenograft models (PMID:35361764); RNA pulldown, Co-IP, migration/invasion assays (PMID:35974702)

    PMID:35361764 PMID:35538152 PMID:35974702

    Open questions at the time
    • RBMS1-MYC chromatin interaction at IL-6 promoter confirmed by single lab only
    • Whether circRNA scaffolding of RBMS1-HuR is a widespread regulatory mechanism is unknown
    • Relative contributions of mRNA stability vs. translation regulation in each cancer context not dissected
  7. 2023 Medium

    Whether RBMS1 regulates ferroptosis beyond SLC7A11 was addressed: RBMS1 overexpression in hepatocellular carcinoma promotes ferroptosis by attenuating GPX4 expression, revealing a second ferroptosis-regulatory axis distinct from the SLC7A11 pathway.

    Evidence RBMS1 overexpression, GPX4 protein measurement, ferroptosis assays in vitro and in vivo, luciferase reporter

    PMID:36989117

    Open questions at the time
    • Direct vs. indirect mechanism of GPX4 attenuation by RBMS1 not resolved
    • Apparent pro-ferroptotic role in HCC contradicts anti-ferroptotic role in lung cancer—context-dependency not mechanistically explained
    • Single lab study
  8. 2024 High

    A second translational co-activator partnership was defined: RBMS1 interacts with the m6A reader YTHDF1 through its RRM2 domain and the YTH domain to promote S100P mRNA translation and NSCLC metastasis, demonstrating that RBMS1 can couple epitranscriptomic reading to translational enhancement.

    Evidence Co-immunoprecipitation, domain mutagenesis, polysome profiling, in vivo mouse metastasis model

    PMID:38342601

    Open questions at the time
    • Transcriptome-wide scope of RBMS1-YTHDF1 co-regulated targets unknown
    • Whether m6A modification on RBMS1-bound mRNAs is required for RBMS1 recruitment not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: what determines whether RBMS1 stabilizes vs. promotes translation of a given mRNA target; how the apparently opposing effects on ferroptosis (pro- in HCC, anti- in lung cancer) are contextually regulated; and what the full repertoire of direct RNA targets and binding motifs is across tissues.
  • No genome-wide CLIP-seq map of RBMS1 binding sites published
  • No structural model of RBMS1 in complex with RNA or protein partners
  • Mechanistic basis for context-dependent pro- vs. anti-metastatic and pro- vs. anti-ferroptotic activity not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 5 GO:0098772 molecular function regulator activity 3 GO:0003677 DNA binding 2 GO:0140110 transcription regulator activity 2
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2
Pathway
R-HSA-8953854 Metabolism of RNA 4 R-HSA-392499 Metabolism of proteins 2 R-HSA-162582 Signal Transduction 1 R-HSA-168256 Immune System 1
Partners
CDKN2B-AS1EIF3DHURMYCYTHDF1

Evidence

Reading pass · 11 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2021 RBMS1 directly interacts with the translation initiation factor eIF3d to bridge the 3'- and 5'-UTR of SLC7A11 mRNA, thereby promoting its translation; RBMS1 ablation inhibited SLC7A11 translation, reduced cystine uptake, and promoted ferroptosis in lung cancer cells. Co-immunoprecipitation, shRNA knockdown, in vitro translation assays, xenograft mouse models The Journal of clinical investigation High 34609966
2020 RBMS1 functions as a post-transcriptional regulator of RNA stability by directly binding target mRNAs; silencing RBMS1 increases metastatic capacity in xenograft models while restoring its expression blunts metastatic liver colonization in colon cancer. PRADA analytic framework applied to clinical/PDX/cell line transcriptomics; RBMS1 KD/OE in xenograft mouse models; direct mRNA binding assays Cancer discovery High 32513775
2022 RBMS1 regulates the mRNA stability of B4GALT1 (a glycosyltransferase of PD-L1); RBMS1 depletion destabilizes B4GALT1 mRNA, inhibits PD-L1 glycosylation, and promotes ubiquitination and degradation of PD-L1, thereby stimulating anti-tumor T cell immunity in triple-negative breast cancer. shRNA screen, mRNA stability assays, Co-immunoprecipitation, ubiquitination assays, in vivo syngeneic mouse models Cell death and differentiation High 35538152
2022 RBMS1 promotes gastric cancer metastasis and EMT by binding transcription factor MYC at the IL-6 promoter (via histone modification influence), transactivating IL-6, and activating downstream JAK2/STAT3 signaling. ChIP assay, Co-immunoprecipitation, in vitro migration/invasion assays, xenograft mouse models Cell death & disease Medium 35361764
2024 RBMS1 interacts with the m6A reader YTHDF1 (via RRM2 motif of RBMS1 and YTH domain of YTHDF1) to promote the translation of S100P mRNA, thereby accelerating NSCLC cell metastasis. Co-immunoprecipitation, domain mutagenesis, polysome profiling/translation assays, in vivo mouse metastasis model Advanced science High 38342601
2012 miR-383 targets RBMS1 by affecting its mRNA stability; RBMS1 suppression by miR-383 reduces c-Myc levels (a downstream target of RBMS1) and enhances estradiol release from mouse ovarian granulosa cells; forced expression of RBMS1 or c-Myc attenuates miR-383-mediated steroidogenesis. miRNA overexpression, luciferase reporter assay, mRNA stability assay, steroidogenesis assay, ChIP Molecular endocrinology Medium 22593182
1994 MSSP-2 (RBMS1 family member/isoform) binds single- and double-stranded DNA at the c-myc gene replication origin/transcriptional enhancer via RNP-1 consensus sequences (RNA recognition motifs); MSSP-2 stimulates DNA replication of an SV40-derived plasmid containing its binding sequence. cDNA cloning, bacterially expressed deletion mutants, DNA binding assays, SV40 plasmid replication assay Nucleic acids research Medium 7838710
1998 Chicken MSSP-1 (RBMS1 ortholog) specifically binds the single-stranded sense strand of a negative cis-element (TATCTTA, -228 to -222) in the alpha-smooth muscle actin promoter and suppresses its transcriptional activity when overexpressed in smooth muscle cells. Gel shift assay, Southwestern blotting, cDNA cloning with anti-MSSP-1 antibodies, promoter-reporter overexpression in cultured smooth muscle cells Nucleic acids research Medium 9580695
2018 Linear CDKN2B-AS1 (ANRIL) lncRNA isoforms directly bind RBMS1 transcripts (shown by RNA immunoprecipitation) and trans-regulate RBMS1 expression; knockdown of CDKN2B-AS1 downregulates RBMS1 at transcript and protein level, independent of cis-regulatory effects. Inducible shRNA knockdown, genome-wide mRNA expression analysis, RNA immunoprecipitation (RIP), Western blot European journal of human genetics Medium 30108282
2022 circEXOC6B acts as a protein scaffold that enhances the binding of RBMS1 and HuR, increasing AKAP12 expression to inhibit prostate cancer metastasis. Co-immunoprecipitation, RNA pulldown, in vitro and in vivo migration/invasion assays Molecular therapy Medium 35974702
2023 In hepatocellular carcinoma, RBMS1 overexpression promotes ferroptosis by attenuating GPX4 expression; the circIDE/miR-19b-3p axis sponges miR-19b-3p to upregulate RBMS1, linking this axis to ferroptosis regulation. RBMS1 overexpression, GPX4 protein measurement, ferroptosis assays in vitro and in vivo, luciferase reporter, RNA pulldown Epigenetics Medium 36989117

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute 406 12671019
2021 RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. The Journal of clinical investigation 260 34609966
1997 Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. British journal of pharmacology 187 9051308
1995 YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. British journal of pharmacology 175 8640334
2007 YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 158 17213816
1998 YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Molecular pharmacology 142 9855623
2001 Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochemical pharmacology 137 11286986
2008 A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Molecular cancer therapeutics 131 19074848
2007 Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression. Molecular pharmacology 125 17513385
1999 Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. Journal of molecular medicine (Berlin, Germany) 105 9930922
2012 Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1. Molecular endocrinology (Baltimore, Md.) 103 22593182
1998 Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chemistry & biology 103 9646941
2000 Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. Biochemistry 82 10747811
2006 A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. International journal of oncology 76 16773207
2022 RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling. Cell death & disease 75 35361764
2003 Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Molecular pharmacology 72 14645672
2004 Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site? Biochemistry 70 15023055
2017 YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells. BioMedicine 65 28612710
2007 Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer letters 65 17502124
2001 YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proceedings of the National Academy of Sciences of the United States of America 64 11687640
2011 Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke. PloS one 63 22110762
2003 A functional domain of the alpha1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding. The Journal of biological chemistry 63 12560334
2002 Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. The Journal of biological chemistry 61 11978784
2022 Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell death and differentiation 57 35538152
2005 Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. The European journal of neuroscience 56 15845095
2007 YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. British journal of pharmacology 54 17401444
2007 Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer biology & therapy 54 18059167
2007 Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics 52 17849408
1999 Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Biochemistry 52 10451364
2020 RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon. Cancer discovery 50 32513775
2006 YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer research 50 16778212
2005 YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. The Journal of pharmacology and experimental therapeutics 49 15784655
2001 NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC pharmacology 49 11801189
1999 A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site? Biochemistry 48 10563809
2004 YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. The Journal of pharmacology and experimental therapeutics 46 15525795
2005 YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Molecular cancer therapeutics 45 16227413
2009 Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. Molecular pharmacology 42 20008515
2003 YC-1 facilitates release of the proximal His residue in the NO and CO complexes of soluble guanylate cyclase. The Journal of biological chemistry 42 12540839
2001 Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Molecular pharmacology 42 11160856
2006 Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochemical and biophysical research communications 41 16919599
2007 Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochemical pharmacology 40 17880926
2014 YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Molecular cancer 39 24418169
2002 Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. International journal of impotence research 39 11979328
2000 YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochemical and biophysical research communications 39 11118339
2023 Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma. Epigenetics 38 36989117
2018 Linear isoforms of the long noncoding RNA CDKN2B-AS1 regulate the c-myc-enhancer binding factor RBMS1. European journal of human genetics : EJHG 37 30108282
2007 Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 37 17312464
2003 YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochemical pharmacology 37 12826268
1994 Molecular cloning of MSSP-2, a c-myc gene single-strand binding protein: characterization of binding specificity and DNA replication activity. Nucleic acids research 37 7838710
1996 Expression of glutathione S-transferases Ya, Yb1, Yb2, Yc1 and Yc2 and microsomal epoxide hydrolase genes by thiazole, benzothiazole and benzothiadiazole. Biochemical pharmacology 36 8951341
2021 Inhibition of hypoxia inducible factor 1 by YC-1 attenuates tissue plasminogen activator induced hemorrhagic transformation by suppressing HMGB1/TLR4/NF-κB mediated neutrophil infiltration in thromboembolic stroke rats. International immunopharmacology 33 33657523
2015 The HIF-1 inhibitor YC-1 decreases reactive astrocyte formation in a rodent ischemia model. American journal of translational research 33 26064442
2013 YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit. Biochemistry 33 24328155
2012 Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. European journal of pharmacology 33 22465181
2004 YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovascular research 33 14732212
2020 YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells. European journal of pharmacology 32 32044322
2005 YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. The Journal of pharmacology and experimental therapeutics 32 16183705
1998 c-Myc gene single-strand binding protein-1, MSSP-1, suppresses transcription of alpha-smooth muscle actin gene in chicken visceral smooth muscle cells. Nucleic acids research 30 9580695
2014 YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. British journal of pharmacology 29 24697523
2006 Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents. Bioorganic & medicinal chemistry 29 17189698
2005 A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thrombosis and haemostasis 29 15886813
2004 Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages. Biochemical pharmacology 29 15013857
2009 Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral oncology 28 19457706
2008 Enhancement of active shuttle avoidance response by the NO-cGMP-PKG activator YC-1. European journal of pharmacology 28 18590724
2004 The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. Journal of pharmacological sciences 28 15037810
2022 The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR. Molecular therapy : the journal of the American Society of Gene Therapy 27 35974702
2011 Blockade of hypoxia-inducible factor-1α by YC-1 attenuates interferon-γ and tumor necrosis factor-α-induced intestinal epithelial barrier dysfunction. Cytokine 26 21890376
2008 YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway. British journal of pharmacology 26 18641674
2002 Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms. Biochemical pharmacology 26 11992625
2022 Circular RNA Rbms1 inhibited the development of myocardial ischemia reperfusion injury by regulating miR-92a/BCL2L11 signaling pathway. Bioengineered 25 35068339
2015 YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. Molecular and cellular endocrinology 25 26159901
2010 Probing soluble guanylate cyclase activation by CO and YC-1 using resonance Raman spectroscopy. Biochemistry 25 20353168
2009 Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. Investigative ophthalmology & visual science 25 19234350
2003 YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. European journal of pharmacology 25 12498924
2000 The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. Journal of cardiovascular pharmacology 25 10710123
2024 RBMS1 Coordinates with the m6A Reader YTHDF1 to Promote NSCLC Metastasis through Stimulating S100P Translation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 23 38342601
2017 Low-dose YC-1 combined with glucose and insulin selectively induces apoptosis in hypoxic gastric carcinoma cells by inhibiting anaerobic glycolysis. Scientific reports 23 28978999
2011 YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice. Pulmonary pharmacology & therapeutics 23 21963997
2005 Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole]. The Journal of pharmacology and experimental therapeutics 23 16352702
2023 HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 22 36822023
2021 Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells. European journal of pharmacology 22 34270985
2014 Effects of YC-1 on learning and memory functions of aged rats. Medical science monitor basic research 22 25144469
1995 Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells. The Biochemical journal 22 7702575
2010 Protective effects of YC-1 against glutamate induced PC12 cell apoptosis. Cellular and molecular neurobiology 21 21063768
2021 Circ-RBMS1 Knockdown Alleviates CSE-Induced Apoptosis, Inflammation and Oxidative Stress via Up-Regulating FBXO11 Through miR-197-3p in 16HBE Cells. International journal of chronic obstructive pulmonary disease 19 34295155
2016 Potent ameliorating effect of Hypoxia-inducible factor 1α (HIF-1α) antagonist YC-1 on combined allergic rhinitis and asthma syndrome (CARAS) in Rats. European journal of pharmacology 19 27498367
2013 The role of heat shock protein 70 in the protective effect of YC-1 on β-amyloid-induced toxicity in differentiated PC12 cells. PloS one 19 23922702
2010 YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Investigational new drugs 19 20676745
2009 Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochemical pharmacology 19 19879857
2004 Resonance Raman study on synergistic activation of soluble guanylate cyclase by imidazole, YC-1 and GTP. Journal of inorganic biochemistry 19 15134928
2001 Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism. Neuropharmacology 19 11684154
2020 YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells. Journal of radiation research 18 32367141
2015 The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents. Organic & biomolecular chemistry 18 26055070
2012 The role of heat shock protein 70 in the protective effect of YC-1 on heat stroke rats. European journal of pharmacology 18 23219797
2010 The guanylyl cyclase activator YC-1 directly inhibits the voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. Journal of pharmacological sciences 18 20093789
2010 Soluble guanylate cyclase is activated differently by excess NO and by YC-1: resonance Raman spectroscopic evidence. Biochemistry 18 20459051
2007 Inhibitory effect of YC-1, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole, on experimental choroidal neovascularization in rat. Ophthalmic research 18 18032914
1999 Soluble guanylate cyclase: effect of YC-1 on ligation kinetics with carbon monoxide. Biochemical and biophysical research communications 18 9920755
2011 Effects of YC-1 targeting hypoxia-inducible factor 1 alpha in oesophageal squamous carcinoma cell line Eca109 cells. Cell biology international 17 20977428
2008 YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells. Molecular pharmacology 17 18923065